

Dr. Elizabeth Poynor

EXPERTISE: GYNECOLOGIC CANCERS/HEREDITARY MALIGNANCIES

- *Ovarian & Primary Peritoneal Cancer*
- *Uterine Cancer*
- *Cervical Cancer*
- *Gestational Trophoblastic Disease*
- *Vaginal & Vulvar Cancer*
- *Hereditary Malignancies*
- *Others*

PROFESSIONAL TRAINING:

Gynecologic Oncology Fellowship: Memorial Sloan Kettering Cancer Center, New York

Residency: Obstetrics & Gynecology: Hospital of the University of Pennsylvania

- *Chief Resident*

Medical School: Columbia University College of Physicians and Surgeons

Doctor of Philosophy (PhD): Cornell University of Graduate School of Medical Sciences

- *Cell Biology and Genetics*

Education: Princeton University: Bachelor of Science in Biology and Biochemistry

ACADEMIC APPOINTMENTS:

Memorial Sloan Kettering Cancer Center: Department of Surgery: 1997-2006; Director of Translational Research 2005-2006

BOARD CERTIFICATIONS:

American Board of Obstetrics & Gynecology: Diplomate of Obstetrics & Gynecology

American Board of Obstetrics & Gynecology: Diplomate of Gynecologic Oncology

CURRENT POSITIONS:

Gynecologic Oncologist: New York City

PROFESSIONAL ACTIVITIES, MEMBERSHIPS & ACCOMPLISHMENTS:

New York Medical Women's Association

American Medical Women's Association

American Medical Association
Medical Society State of New York
New York County Medical Society
Society of Gynecologic Oncologists
Society of Memorial Gynecologic Oncologists
Metropolitan Gynecologic Oncology Society
American Society Clinical Oncologists
Fellow, American College of Obstetricians and Gynecologists
North American Menopause Society
Society of Laparoendoscopic Surgeons
American Association of Gynecologic Laparoscopists

RESEARCH:

Cornell Graduate School of Medical Sciences **1998-2004**

Sloan Kettering Institute

Principal Investigator

Extensive work with the genetics and molecular biology of ovarian cancer, including gene expression microarray analysis.

Memorial Sloan-Kettering Cancer Center **2004-2006**

Principal Investigator

defining the role of the angiogenic response in tumor sensitivity to ionizing radiation.

CLINICAL RESEARCH:

Memorial Sloan-Kettering Cancer Center

2003-2004 A Phase I, Open-Label, Multicenter Study to Evaluate the Effect of Tumor-Based Her2 Activation on the Efficacy of Rhumab 2C4 (pertuzumab) in Subjects with Advanced, Refractory, Or Recurrent Ovarian Cancer (toc2689g) Co-principal investigator

2003-2006 A Phase II Study of Cetuximab (c225)/paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Co-investigator

2001-2002 Phase I Trial of Ps-341 (nsc 681239) and Carboplatin in Recurrent Or Progressive Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Or Fallopian Tube Cancer Co-investigator

2002-2004 Phase I Trial of the Monoclonal Anti-Idiotypic Antibody Aca125 in Patients with Epithelial Ovarian, Fallopian Tube, Or Peritoneal Cancer Co-principal investigator

2002-2006 Postoperative Recovery in Patients Receiving Patient-Controlled Epidural Analgesia (pcea) Compared to Patient-Controlled Intravenous Analgesia (pca) after Major Open Gynecologic Surgery: A Randomized Controlled Trial Co-investigator

PRESENTATIONS:

1. *"Genetics of Ovarian Cancer"*
Memorial Sloan-Kettering Cancer Center
1997
2. *"Commentary on Ovarian Cancer"*
MSNBC invited guest host
1997
3. *"Biologic Treatments for Gynecologic Cancers"*
"Laparoscopy in the management of Gynecologic Cancers"
Invited Speaker
Guayaquil, Republic of Ecuador
1999
4. *"Cancers in Pregnancy"*
Gynecologic Care of the Cancer Patient
Memorial Sloan Kettering Cancer Center
1999
5. *"Cervical Cancer- New Radiation Protocols"*
Invited speaker
United Arab Emirates Annual Cancer Conference
Abu Dhabi, UAE
2000
6. *"Prophylactic Oophorectomy"*
Gynecologic Care of the Cancer Patient
Memorial Sloan Kettering Cancer Center
2000
7. *"Ovarian Cancer and Hormone Replacement Therapy"*
Invited commentary, NBC Today Show
2001
8. *"Blood Test for Ovarian Cancer"*
Invited commentary, ABC World News Tonight
2002
9. *"Targeted Treatments for Gynecologic Malignancies"*
and Course Director
Gynecology Disease Management Team Course
"Emerging Treatments for Gynecologic Malignancies"
2003
10. *"Cervical Cancer Screening"*
CancerSmart
Memorial Sloan-Kettering Cancer Center
2004

11. *"Lactose and Ovarian Cancer"*
Invited commentary
UPN Channel 9 News
2004
12. *"Progress in Ovarian Cancer Treatment"*
Invited speaker
New York Ovarian Cancer Coalition
2004
13. *"Emerging Treatments for Gynecologic Cancers"*
Invited speaker
Gilda's Club of Westchester, New York
2004
14. *"Hormone Replacement Therapy and the Women's Health Initiative"*
"Genetics and Cancer Risk Management"
Invited speaker
Grand Rounds Day
Henry Ford Hospital
Detroit, Michigan
2004
15. *"Prophylactic Surgery for the Prevention of Ovarian Cancer"*
and Moderator
International Conference on Ovarian Cancer
MD Anderson Cancer Center
Houston, Texas
2004
16. *"ZIC2 and Epithelial Ovarian Cancer"*
Surgical Grand Rounds
Memorial Sloan Kettering Cancer Center
2004
17. *"Microarray Analysis of Epithelial Ovarian Cancer"*
Surgical Research Conference
Memorial Sloan Kettering Cancer Center
2004
18. *"Tumor Endothelium as a Target for Ionizing Radiation"*
Surgical Chairman's Conference
Memorial Sloan Kettering Cancer Center
2004
19. *"Update on the Society of Gynecologic Oncologists Meeting"*
Invited speaker
SHARE

New York, New York
2005

20. *"Molecular Oncology and Targeted Treatments"*
Invited Speaker
Florida Obstetric and Gynecologic Society
Jacksonville, Florida
2005
21. *"Exploring the Connection Between Breast and Ovarian Cancer"*
Invited Speaker
Sharsharet
Teakneck, NJ
2006
22. *"Genetic Basis for Ovarian Cancer"*
Invited Speaker
Central Synagogue
New York, NY
2007
23. *"BRCA1 and BRCA2 Testing"*
Invited Speaker
Beth Israel Medical Center
New York, NY
2009
24. *"Trends in Gynecologic Oncology"*
Grand Rounds
Lenox Hill Hospital
New York, New York
2010
25. *"BRCA1 and BRCA2 Testing"*
Invited Round Table Speaker
Myriad Genetics
New York, NY

PUBLICATIONS:

1. Poynor EA and Hoskins WJ. *The role of second-look surgery in the management of epithelial ovarian cancer. Contemp Oncol 1995. Special Report on Ovarian Cancer: State of the art diagnosis and management. Ed. J.R. Lurain.*
2. Poynor EA. *Managing cervical adenocarcinoma in situ. OBG Management. August 1998: 47-57.*
3. Poynor EA. *Cancer Screening for Women. Oncology Special Edition 1999;2: 108-110.*

4. *Poynor EA, Hoskins WJ. Cancer of the Ovary. Bland KI, Daly JM, Karakousis CP (Eds.). Surgical Oncology: Contemporary Principles and Practice. McGraw Hill, 2001:911-950.*
5. *Poynor EA and Offit K. Ovarian cancer with a family History. Lederman JA, Hoskins WJ, Kaye SB, Vegote I (Eds.) Clinical management of Ovarian Cancer. London: Martin Dunetz, 2001:215-228.*
6. *Poynor EA, Barakat RR, Hoskins WJ. The management and follow-up of adenocarcinoma in situ of the uterine cervix. Gynecol Oncol 1995; 57:158-164.*
7. *Boyd J, Sonoda Y, Federici MG, Bogomoliny F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ. Clinicopathologic features of BRCA1-linked and sporadic ovarian cancer. JAMA. 2000; 283(17):2260-5.*
8. *Husain A, Curitn J, Corrigan K, Brown C, Poynor E, Chi D, Barakat RR. Continent urinary diversion in patients undergoing exenterative or palliative procedures for recurrent gynecologic cancers. Gynecol Oncol 2000; 78(2):208-11.*
9. *Sills ES, Poynor EA, Moomjy M. Ovarian hyperstimulation following accidental daily clomiphene citrate use over three consecutive months. Reprod Toxicol 2000;14:541-543.*
10. *Husain A, Chi DS, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP. The role of laparoscopy in second look evaluations for ovarian cancer. Gynecol Oncol 2001 Jan;80(1):44-7.*
11. *Dizon DS, Hensley M, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, Venkatraman E , and Spriggs DR. Retrospective analysis of carboplatin and paclitaxel as first-line salvageinitial second-line therapy for recurrent epithelial ovarian carcinoma. J Clin Oncol 2002 Mar 1;20(5):1238-47.*
12. *Mark Robson, Martee Hensley; Richard Barakat; Carol Brown; Dennis Chi; Elizabeth Poynor; Kenneth Offit. Quality of Life in Women at Risk for Ovarian Cancer who have Undergone Risk-Reducing Oophorectomy. Gynecol Oncol. 2003 May;89(2):281-7.*
13. *Abu-Rustum NR, Chi DS, Sonoda Y, DiClemente MJ, Bekker G, Gemignani M, Poynor E, Brown C, Barakat RR. Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique. Gynecol Oncol. 2003 Jun;89(3):504-13*
14. *Levine DA, Villella JA, Poynor EA, Soslow RA. Gastrointestinal adenocarcinoma arising in a mature cystic teratoma of the ovary. Gynecol Oncol. 2004 Aug;94(2):597-9.*
15. *Miner TJ, Delgado R, Zeisler J, Busam K, Alektiar K, Barakat R, Poynor E. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol. 2004 Jan;11(1):34-9.*
16. *Abu-Rustum NR, Gemignani ML, Moore K, Sonoda Y, Venkatraman E, Brown C, Poynor E, Chi DS, Barakat RR. Total laparoscopic radical hysterectomy with pelvic*

- lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecol Oncol. 2003 Nov;91(2):402-9. Erratum in: Gynecol Oncol. 2004 Apr;93(1):275*
17. *Sonoda Y, Abu-Rustum NR, Gemignani ML, Chi DS, Brown CL, Poynor EA, Barakat RR. A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? Gynecol Oncol. 2004 Dec;95(3):534-8.*
 18. *Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004 Sep;94(3):650-4.*
 19. *Bochner BH, McCreath WA, Aubey JJ, Levine DA, Barakat RR, Abu-Rustum N, Poynor E, Wong D, Chi DS. Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. Gynecol Oncol. 2004 Jul;94(1):140-6.*
 20. *Sonoda Y, Abu-Rustum NR, Gemignani ML, Chi DS, Brown CL, Poynor EA, Barakat RR. A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible? Gynecol Oncol. 2004 Dec;95(3):534-8.*
 21. *Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol. 2005 Jun;97(3):916-23.*
 22. *Poynor EA, Marshall D, Sonoda Y, Slomovitz BM, Barakat RR, Soslow RA. Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization. Gynecol Oncol. 2006 Dec;103(3):960-5.*
 23. *Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006 Dec;103(3):1083-90.*
 24. *Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res. 2006 Sep 15;12(18):5503-10.*
 25. *Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2007 Jan;104(1):176-80.*

ABSTRACTS:

1. *Poynor EA, Barakat RR, Curtin JP, Hoskins WJ. The role of bowel surgery in the management of epithelial ovarian cancer. Presented at the 1995 meeting of the Society of Surgical Oncology.*
2. *Poynor E, Barakat R, Brown K, Offitt K, Corrigan K, Hoskins WJ. Clinicopathologic features of familial and hereditary ovarian cancers. Gynecol Oncol 1996; 60:114.*
3. *Boyd J, Sonoda Y, Federici MG, Bogomolny F, Rhei E, Maresco DL, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ. Clinical and Pathologic Features of Hereditary Ovarian Cancers Associated with Germline Mutations in BRCA1 or BRCA2. Abstract # 6. The 30th Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 1999;72:444.*
4. *Aghajanian C, Sabbatini P, Hensley M, Tong W, Soignet S, Hoskins W, Brown C, Poynor E, O'Connor K, Pezzulli S, Barakat R, Spriggs D. A Phase I Trial of Intraperitoneal (IP) Cisplatin with IP Gemcitabine in Patients (Pts) with Epithelial Ovarian Cancer. Abstract # 1428. ASCO 35th Annual Meeting, 1999.*
5. *Husain A, Chi DS, Prasad M, Abu-Rustum NR, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP. The Role of Laparoscopy in Second-Look Evaluations for Ovarian Cancer. Poster presentation. SGO 31st Annual Meeting, 2000.*
6. *Sonoda Y, Zerbe M, Barakat RR, Brown CL, Chi DS, Poynor EA, Hoskins WJ. High Incidence of Positive Peritoneal Cytology in Low-Risk Endometrial Cancer Treated by Laparoscopically Assisted Vaginal Hysterectomy (LAVH). Abstract #19. 31st Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 2000;76(2):235.*
7. *Husain A, Chi DS, Prasad Manju, Abu-rustum NR, Barakat RR, Brown CL, Poynor EA, Hoskins WJ, Curtin JP. The Role of Laparoscopy in Second-look Evaluations for Ovarian Cancer. Abstract #85. 31st Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 2000;76(2):253.*
8. *Sonoda Y, Husain A, Sabbatini P, Chi DS, Poynor EA, Brown CL, Hoskins WJ, Barakat RR. A Comparison of Paclitaxel-Based Chemotherapy in Papillary Serous Carcinoma of the Peritoneum (PSCP) and Papillary Serous Carcinoma of the Ovary (PSCO). Poster presentation. Abstract #87. 31st Annual Meeting of the Society of Gynecologic Oncologist, Feb. 5-9, 2000. Gynecol Oncol 2000;76(2):253.*
9. *Poynor EA, Luzzatto LL, Federici MG, Boyd JA, Hoskins WJ. Use of Microarray Technology in the Investigation of the Genes Important in the Pathogenesis of Epithelial Ovarian Cancer (EOC). Poster presentation. Abstract #91. 31st Annual Meeting of the Society of Gynecologic Oncologist, Feb. 5-9, 2000.*
10. *Sonoda Y, Zerbe M, Barakat RR, Brown CL, Chi DS, Poynor EA, Hoskins WJ. High Incidence of Positive Peritoneal Cytology in Low-Risk Endometrial Cancer Treated by Laparoscopically Assisted Vaginal Hysterectomy (LAVH). Abstract. The 2000 SmithKline*

Beecham National Gynecologic Oncology Fellows' Forum. February 24-27, 2000, San Diego, California.

11. *Dennis S. Chi, Corinna C. Franklin, Douglas A. Levine, Faina Akselrod, Paul Sabbatini, William R. Jarnagin, Ronald Dematteo, Elizabeth A. Poynor, Nadeem Abu-Rustum, Richard R. Barakat. Improved Optimal Cytoreduction Rates for Stage IIIC and IV Epithelial Ovarian Cancer: Change in Surgical Approach. Abstract #44. 34th Annual Meeting of the Society of Gynecologic Oncologist, January 31 - February 4, 2003.*
12. *Nadeem Abu-Rustum, Dennis S. Chi, Yukio Sonoda, M. J. Diclemente, G. Bekker, Carol L. Brown, Elizabeth A. Poynor, Mary L. Gemignani, Richard R. Barakat. Memorial Sloan-Kettering Cancer Ctr, New York, NY. Low Complication Rate of Laparoscopic Pelvic and Aortic Lymph Node Dissection Using the Argon-Beam Coagulator or Monopolar Instruments: An 8-Year Study Abstract #: 97 :34th Annual Meeting January 31 - February 4, 2003.*
13. *Nadeem Abu-Rustum, Dennis S. Chi, Yukio Sonoda, Carol L. Brown, Mary L. Gemignani, Elizabeth A. Poynor, Richard R. Barakat. Memorial Sloan-Kettering Cancer Ctr, New York, NY. Trocar-Related Tumor Implantation: A Review of 1080 Transperitoneal Laparoscopies in Women with Malignant Disease. Abstract #: 97:34th Annual Meeting January 31 - February 4, 2003.*
14. *Elizabeth A. Poynor, Valbona Behaj, Andrew J. Meltzer, Andrew C. Koff, Richard R. Barakat, Jeff A. Boyd. Memorial Sloan-Kettering Cancer Ctr, New York, NY. ZIC2 Gene Expression in Epithelial Ovarian Cancer Abstract #: 200 34th Annual Meeting January 31 - February 4, 2003 .*